284 related articles for article (PubMed ID: 8442275)
21. Immunological analysis of kidney allograft infiltrates during rejection: presence of cells coexpressing CD4 and CD8 antigens.
Trovati A; Cinti P; Tamburro ML; Lattanzi R; Baiano V; Orlandini AM; Renna Molajoni E; Cortesini R
Transplant Proc; 1995 Feb; 27(1):930-1. PubMed ID: 7879236
[No Abstract] [Full Text] [Related]
22. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
23. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
24. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells.
Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T
Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885
[No Abstract] [Full Text] [Related]
25. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
26. Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation.
Mestre M; Bas J; Alsina J; Grinyó JM; Buendia E
Transplant Proc; 1999 Sep; 31(6):2254-5. PubMed ID: 10500565
[No Abstract] [Full Text] [Related]
27. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J
Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797
[No Abstract] [Full Text] [Related]
28. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
29. Treatment with poly- and monoclonal antilymphocyte antibodies: assessment of efficacy and safety in transplantation.
Claesson K; Tufveson G; Wahlberg J
Transplant Proc; 1992 Feb; 24(1):314. PubMed ID: 1539293
[No Abstract] [Full Text] [Related]
30. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
Hesse UJ; Wienand P; Baldamus C; Arns W
Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
[No Abstract] [Full Text] [Related]
31. Anti-B lymphocytotoxins in renal-allograft rejection.
Ettenger RB; Terasaki PI; Ting A; Malekzadeh MH; Pennisi AJ; Uittenbogaart C; Garrison R; Fine RN
N Engl J Med; 1976 Aug; 295(6):305-9. PubMed ID: 778617
[TBL] [Abstract][Full Text] [Related]
32. Serial changes in the expression of CXCR3 and CCR5 on peripheral blood lymphocytes following human renal transplantation.
Inston N; Drayson M; Ready A; Cockwell P
Exp Clin Transplant; 2007 Dec; 5(2):638-42. PubMed ID: 18194114
[TBL] [Abstract][Full Text] [Related]
33. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
34. Prognostic significance of T cell associated surface antigen density changes during OKT3 therapy of renal allograft rejection.
Shabtai M; Waltzer WC; Dominguez-Rafer C; Pullis CK; Malinowski K; Raisbeck AP; Rapaport FT
J Urol; 1991 May; 145(5):928-31. PubMed ID: 1901920
[TBL] [Abstract][Full Text] [Related]
35. Lymphocyte propagation from biopsies of kidney allografts.
Engstrand M; Larsson E; Naghibi M; Tufveson G; Korsgren O; Johnsson C
Transpl Immunol; 2006 Nov; 16(3-4):215-9. PubMed ID: 17138056
[TBL] [Abstract][Full Text] [Related]
36. Cells infiltrating rejected human kidney allografts secrete IFN-gamma, IL-6, and IL-10, and are modulated by IL-2 and IL-4.
Merville P; Pouteil-Noble C; Wijdenes J; Potaux L; Touraine JL; Banchereau J
Transplant Proc; 1993 Feb; 25(1 Pt 1):111-3. PubMed ID: 8438243
[No Abstract] [Full Text] [Related]
37. The effect of major histocompatibility complex matching on renal pathology and OKT4/OKT8 (CD4/CD8) ratio in renal allograft rejection.
Smart YC; Nanra RS; Hibberd AD; Burton RC
Transplant Proc; 1987 Feb; 19(1 Pt 2):1627-8. PubMed ID: 3152632
[No Abstract] [Full Text] [Related]
38. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
[No Abstract] [Full Text] [Related]
39. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation.
Buchler M; Thibault G; al Najjar A; Valentin JF; Guerraoui A; Nivet H; Bardos P; Lebranchu Y
Transplant Proc; 1996 Oct; 28(5):2817-8. PubMed ID: 8908076
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
